ArticleFrontiers in immunology2025

Cadonilimab plus chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis.

Zuojuan Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.